Joshua Isner Sells 20,000 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) President Joshua Isner sold 20,000 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the sale, the president owned 249,502 shares in the company, valued at approximately $137,874,805.20. This trade represents a 7.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Joshua Isner also recently made the following trade(s):

• On Wednesday, December 3rd, Joshua Isner sold 2,041 shares of Axon Enterprise stock. The stock was sold at an average price of $535.11, for a total transaction of $1,092,159.51.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $568.39 on Thursday. The company has a market cap of $44.85 billion, a P/E ratio of 179.87, a P/E/G ratio of 125.55 and a beta of 1.40. The firm’s fifty day moving average price is $629.76 and its two-hundred day moving average price is $716.48. Axon Enterprise, Inc has a one year low of $469.24 and a one year high of $885.91. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The company had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. During the same quarter in the prior year, the business posted $1.45 EPS. The business’s quarterly revenue was up 30.6% compared to the same quarter last year. Equities analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Institutional Investors Weigh In On Axon Enterprise

Large investors have recently bought and sold shares of the company. Stone House Investment Management LLC bought a new stake in shares of Axon Enterprise during the 3rd quarter worth approximately $29,000. New Millennium Group LLC bought a new stake in Axon Enterprise during the third quarter worth $29,000. Hemington Wealth Management boosted its holdings in shares of Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 17 shares in the last quarter. Whipplewood Advisors LLC boosted its holdings in shares of Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 27 shares in the last quarter. Finally, Darwin Wealth Management LLC bought a new position in shares of Axon Enterprise in the 2nd quarter valued at $37,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on AXON shares. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. JMP Securities reaffirmed a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a report on Monday, September 29th. Barclays dropped their target price on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $870.00 target price on shares of Axon Enterprise in a research report on Wednesday, September 24th. Finally, Royal Bank Of Canada assumed coverage on shares of Axon Enterprise in a research report on Monday, November 17th. They set an “outperform” rating and a $860.00 price target on the stock. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $815.00.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.